The evidence that BCL-2 is expressed in almost all AML cells and that, in young patients, its overexpression predicts lower CR rate and worse survival [2,9,10,11] offers an attractive option in patients ineligible for intensive chemotherapy [12,13,14]. The gene discussed is BCL2; the disease is acute myeloid leukemia.